Bpifrance

Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

MB Therapeutics is a pharmaceutical company that specializes in patient-centric solutions for the development and production of tailored medicines. It operates a system that enables the creation of customized medications, including the combination of multiple active ingredients into a single unit, and offers evaluation services. The company's focus is on enhancing treatment precision and improving patient adherence through the customization of medication dosage and forms.

NEBULA maps 3D macromolecule using dataset-free genAI and physics, enhancing drug target discovery, which forms the basis of all new drugs.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutics. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to address treatment resistance and enhance cancer cell survival. Its therapeutic offerings are particularly aimed at the treatment of gastrointestinal cancers, providing potential solutions for patients facing these challenging conditions.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Theremia is a health technology company that leverages artificial intelligence to transform drug development, with a focus on neurological disorders. It employs advanced machine learning to optimize drug compounds for specific demographic groups, enhancing treatment effectiveness and reducing adverse effects.

Vaxinano is a biotechnology company focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Established in 2016, Vaxinano builds on 25 years of research and clinical trials related to vaccines, utilizing the patented technology of Pr Didier Betbeder. The company specializes in creating safe-by-design nanoparticles that adhere to green chemistry principles, which support the development of prophylactic and therapeutic vaccines for infectious diseases. Additionally, Vaxinano aids medical researchers in formulating drugs that activate biomolecules, proteins, and antigens, thereby facilitating innovative approaches to combat untreated viral, bacterial, and parasitic diseases.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Biodol Therapeutics SAS, founded in 2015 and located in Clapiers, France, focuses on developing innovative treatments for chronic pain. The company has identified the receptor tyrosine kinase FLT3 as a critical factor in triggering and sustaining chronic neuropathic pain. Through its proprietary approach, Biodol Therapeutics develops extracellular inhibitors of the FLT3 receptor, which aim to inhibit ligand binding and thereby alleviate conditions such as allodynia, pain hypersensitivity, and spontaneous pain without disrupting normal nervous system function. Additionally, research partnerships have indicated that inhibiting FLT3 may enhance the efficacy of opioids, potentially reducing their associated risks, including addiction. This innovative work positions Biodol Therapeutics as a significant player in addressing chronic pain and contributing to solutions for the opioid crisis.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

AQEMIA is a pharmatech company focused on drug discovery, utilizing a platform that integrates machine learning with quantum-inspired physics. This innovative approach allows for the efficient identification of new drug candidates aimed at specific therapeutic targets. By employing advanced algorithms, AQEMIA's platform is capable of predicting the interactions and affinities between potential drug molecules and their targets. This methodology not only accelerates the drug discovery process but also contributes to a growing pipeline of viable drug candidates for various medical applications.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Quobly specializes in the development and marketing of a universal large-scale quantum computer, leveraging established semiconductor industry techniques. The company focuses on creating quantum computing semiconductors designed for commercial applications, enabling clients to utilize quantum computers for various complex problems. These applications include optimizing energy distribution and accelerating drug development by computing chemical properties more efficiently. Quobly aims to meet the specific needs of its clients by providing reliable and effective quantum computing solutions based on proven semiconductor processes.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The company aims to create medicinal chemistry solutions that address key cellular mechanisms responsible for the survival and aggressiveness of both solid tumors and hematological cancers. By utilizing a first-in-class approach, Kairos Discovery seeks to provide breakthrough technology in oncology, ultimately improving the lives of cancer patients and their families.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, dedicated to enhancing data collection processes in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has developed expertise in eCOA solutions applicable across all phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. To meet the evolving demands of clinical research, Kayentis offers a comprehensive suite of services that prioritize scientific integrity and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, the company's technology facilitates electronic data capture, providing a versatile range of tools designed to simplify data collection for both patients and clinical trial sites.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutics. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to address treatment resistance and enhance cancer cell survival. Its therapeutic offerings are particularly aimed at the treatment of gastrointestinal cancers, providing potential solutions for patients facing these challenging conditions.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

Jalon Therapeutics is focused on developing innovative therapies that target essential tumor signaling pathways that have not yet been addressed. The company aims to transform the lives of cancer patients by creating medicines that effectively inhibit these pathways. Through its research, Jalon Therapeutics explores the potential of non-oncogene addiction to discover new therapeutic targets and develop groundbreaking anticancer treatment strategies. The company's work is centered on improving treatment options for individuals battling cancer, ultimately striving to enhance their quality of life.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Guerbet is a healthcare company focused on medical imaging, with a history spanning 90 years. As a pioneer in contrast media, it is the only pharmaceutical group dedicated exclusively to this field. Guerbet operates in nearly 80 countries through a network of subsidiaries and distributors, providing a wide array of products for various imaging modalities, including CT scans, magnetic resonance imaging (MRI), ultrasound, and nuclear medicine. The company’s portfolio includes well-known brands such as Xenetix, Optiray, Dotarem, and Telebrix, among others. Additionally, Guerbet offers injectors and related medical devices aimed at enhancing patient diagnosis, prognosis, and overall quality of life.

Apmonia Therapeutics is focused on developing next-generation peptide-based therapies aimed at improving treatment options for various types of cancer, including glioblastoma, ovarian, colorectal, and pancreatic cancers. The company concentrates on targeting the tumor microenvironment, which plays a crucial role in cancer progression. By creating innovative drugs, Apmonia Therapeutics seeks to enhance therapeutic strategies for solid tumors and provide new perspectives in cancer treatment. Their approach includes the development of personalized immunotherapy solutions that utilize proprietary therapeutic peptides, ultimately aiming to improve the quality of life for patients battling cancer and assisting researchers in their efforts to advance cancer therapies.

DeepLife is a biotech company based in Paris, France, founded in 2019. It focuses on developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This approach allows the identification of new drug targets, biomarkers, and potential drug candidates, enabling a better understanding of drug resistance and sensitivity. The company's mission is to advance systems biology and facilitate the transition of laboratory discoveries to clinical applications. DeepLife collaborates with academic institutions to leverage expertise and drive innovation in the biopharmaceutical industry, ultimately aiming to match the right drug to the right patient.

Qairn specializes in digitizing regulatory processes for healthcare manufacturers, including laboratories, medical devices, and biotechs. The company offers a SaaS platform that streamlines and secures mandatory procedures, facilitating the management of promotional materials and other regulated content. Qairn's services include the review and validation of promotional documents, submission to ANSM, and compliance support, allowing clients to efficiently navigate regulatory requirements while minimizing risks. By simplifying these processes, Qairn enables its clients to focus on innovation and improving healthcare outcomes.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Brenus Pharma is focused on developing cell-based immunotherapies aimed at treating solid tumors. The company utilizes an allogeneic platform to create anti-cancer cell vaccines, which leverage the patient's immune system to combat cancer and reduce the risk of treatment resistance. Their approach emphasizes generating multiple candidate therapies efficiently, allowing for cost-effective scaling and integration with existing treatment standards. With a strong intellectual property portfolio and a team of experienced professionals, including renowned oncologists, Brenus Pharma seeks to educate the immune system to recognize and respond to tumor-associated and tumor-specific antigens, enhancing the effectiveness of chemotherapy and radiotherapy in cancer care.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

Diaccurate is a biotechnology company based in Paris, France, that focuses on researching and developing treatments for various diseases, including HIV infection and several types of cancer. Founded in 2012, the company targets conditions such as endocrine-resistant metastatic breast tumors, glioblastoma, and refractory acute myeloid leukemia. Diaccurate is dedicated to exploring innovative therapeutic approaches in oncology, aiming to provide effective solutions for patients facing these challenging and often incurable diseases.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.

Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.

Egle Therapeutics SAS is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing innovative immunotherapies that target immune suppressor regulatory T-cells (Tregs) for the treatment of oncology and autoimmune diseases. The company's research focuses on a proprietary drug pipeline that includes computationally designed IL-2 variants aimed at modulating Treg activity. This approach seeks to either engage or dis-engage Tregs, facilitating the development of therapies that can effectively combat cancer and other related conditions by addressing the immune suppression caused by Tregs. Egle Therapeutics aims to advance its unique portfolio to provide new treatment options in the healthcare field.

Provepharm Life Solutions SA is a life sciences company based in Marseille, France, specializing in contract research and development services for small molecules and therapeutic peptides. Founded in 1998, the company focuses on the development, manufacturing, and marketing of pharmaceutical products and active ingredients. A key offering is pharmacopoeial grade methylene blue, a versatile compound utilized in various human health applications, including as an antidote for methemoglobinemia, a mild urinary antiseptic, and a topical antiseptic. The company also addresses animal health needs, providing solutions for toxicosis and aquaculture. Methylene blue serves additional roles as a laboratory dye, indicator, and diagnostic aid in surgical procedures. Provepharm Life Solutions aims to lead in the life sciences sector through its innovative approach, known as Molecule Vitalization, and offers a range of research and manufacturing services to advance health solutions.

Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

AQEMIA is a pharmatech company focused on drug discovery, utilizing a platform that integrates machine learning with quantum-inspired physics. This innovative approach allows for the efficient identification of new drug candidates aimed at specific therapeutic targets. By employing advanced algorithms, AQEMIA's platform is capable of predicting the interactions and affinities between potential drug molecules and their targets. This methodology not only accelerates the drug discovery process but also contributes to a growing pipeline of viable drug candidates for various medical applications.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

Olgram is a biotechnology company focused on developing innovative solutions to combat chronic bacterial infections and address immune deficiencies resulting from conditions like traumatic brain injury and concussions. The company specializes in marine molecules, particularly those derived from algae, to create new products that target dormant bacteria responsible for infectious relapses. Through its research, Olgram is pioneering a new class of anti-infectives aimed at effectively eliminating persistent bacterial strains. Its dual approach not only seeks to treat stubborn bacterial infections but also aims to enhance immune responses, thereby contributing to more effective treatments for patients suffering from various infectious diseases.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

Seekyo is a privately-owned biotech company focused on developing advanced chemotherapies that specifically target the microenvironment of solid tumors. Its innovative approach aims to deliver potent anticancer agents while minimizing harm to healthy tissues, thereby reducing adverse effects for cancer patients. The company's "smart drugs" are designed to selectively transport these agents, utilizing a targeting unit for effective recognition of malignant cells. Additionally, Seekyo's technology incorporates a versatile enzyme-responsive self-immolative linker that enables controlled drug release exclusively at the tumor site. This targeted methodology seeks to enhance the efficacy and safety of cancer treatments, offering patients a more tolerable therapeutic option.

CVasThera is a biopharmaceutical company focused on creating innovative therapies for cardiovascular and bowel diseases, particularly targeting conditions such as Crohn's disease. The company has secured an exclusive global license for two patents that emerged from four years of collaborative research involving the French National Institute of Health and Medical Research and the École des Mines d’Albi. By leveraging this research, CVasThera aims to provide effective treatment options for patients experiencing moderate to severe flare-ups, especially those reliant on corticosteroids.

Iktos is a French company focused on artificial intelligence and robotic solutions for medicinal chemistry and drug design. It offers a proprietary generative AI technology that optimizes molecule design for small molecule discovery projects, significantly enhancing productivity in pharmaceutical research and development. Iktos provides its innovative solutions through its SaaS platforms, Makya™ for generative drug design and Spaya™ for retrosynthesis, while also engaging in strategic partnerships with pharmaceutical companies to accelerate drug discovery. Additionally, Iktos has developed an AI-driven synthesis automation platform, Iktos Robotics, which expedites the Design-Make-Test-Analyze cycle in drug development. The company is also advancing its own pipeline of drug candidates aimed at oncology and autoimmune diseases. In March 2023, Iktos secured a significant financing round, and in July 2024, it enhanced its capabilities by acquiring Synsight, which adds a biology platform for discovering drugs targeting Protein-Protein and RNA-Protein interactions.

NovAliX is a biotechnology company specializing in drug discovery and development services for the pharmaceutical industry. It offers a range of integrated services, including enabling chemistry and biophysical technologies, to support clients from discovery to manufacturing. Key capabilities include proprietary Surface Plasmon Resonance (SPR) technology, X-ray protein crystallography, supramolecular mass spectrometry, and advanced Nuclear Magnetic Resonance (NMR) technologies. These are used for comprehensive small molecule drug discovery, fine characterization of biologics, thorough analysis of Active Pharmaceutical Ingredients (APIs), and polymorphism studies, supporting pharmaceutical development and manufacturing teams.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, dedicated to enhancing data collection processes in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has developed expertise in eCOA solutions applicable across all phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. To meet the evolving demands of clinical research, Kayentis offers a comprehensive suite of services that prioritize scientific integrity and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, the company's technology facilitates electronic data capture, providing a versatile range of tools designed to simplify data collection for both patients and clinical trial sites.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

Advicenne is a late-stage biopharmaceutical company founded in 2007 and headquartered in Nîmes, France. The company focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly targeting orphan renal diseases and niche neurology indications. Its lead drug candidate, ADV7103, is undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the lives of patients from early childhood through adulthood.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

SideROS is a biotechnology company based in Paris, France, established in 2019. The company focuses on researching iron-targeting chemical compounds to develop drug candidates aimed at persister cancer cells, which are resistant to conventional treatments and linked to metastasis and relapse. One of its key developments is ironomycin, a chemical molecule that disrupts iron homeostasis in persister cancer cells, leading to cell death through a process known as ferroptosis. By targeting these resilient cancer cells, SideROS aims to advance cancer treatment options.

Synapse Medicine, founded in 2017 and based in Bordeaux, France, specializes in developing an online platform that supports healthcare professionals in managing drug prescriptions. The company's platform offers a comprehensive global knowledge base, utilizing algorithms to ensure the information is reliable and up-to-date. This service helps doctors and pharmacists access accurate medication data, enabling them to analyze treatments in real-time and enhance the safety of drug therapies. Synapse Medicine collaborates with leading hospitals and digital health companies across the United States, Europe, and Japan to transform medication management, aiming to improve overall medication success for patients.

ABC Transfer is a biopharmaceutical company that specializes in the development of Rapid Transfer Systems (RTS) for the pharmaceutical industry. The company manufactures secure transfer systems designed specifically for sterile drug manufacturing and bioprocessing. Its innovative solutions include alpha doors, beta containers, and single-use bags, all built on patented designs. These systems enhance sterility assurance, improve operator safety, and increase overall efficiency in drug manufacturing processes. Through its focus on secure and efficient transfer methods, ABC Transfer aims to support the biopharmaceutical industry's critical need for reliable and safe drug production.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Syndivia is a biotechnology company focused on developing innovative cancer therapeutics aimed at treating patients with challenging cancer indications. The company leverages the unique properties of tumor hallmarks and the tumor microenvironment to create targeted antibody-drug conjugates (ADCs) that feature optimal drug-to-antibody ratios. By doing so, Syndivia aims to enhance antitumor efficacy and improve safety for cancer patients, ultimately striving to deliver the most effective treatments available.

Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.

Fab'entech, founded in 2009 in Lyon, France, is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂] to address emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab'entech provides healthcare institutions with effective treatments for emergency situations. As a member of the LyonBiopôle cluster, the company is positioned within a network that fosters biotechnological advancements in the region.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

Aelis Farma S.A.S. is a biotechnology company based in Bordeaux, France, established in 2013. The company specializes in the research and development of pregnenolone derivatives aimed at treating cannabis addiction. Aelis Farma is recognized for its innovative approach in developing signaling-specific therapeutics that target G protein-coupled receptors (GPCRs), particularly the CB1 receptor, which is widely expressed in the brain. By focusing on these receptors, Aelis Farma aims to create treatments that can selectively modulate signaling pathways, minimizing unwanted side effects commonly associated with conventional GPCR-targeting drugs. The company's work addresses critical needs in the treatment of brain diseases and addiction.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

NH TherAguix SAS is a clinical stage pharmaceutical company based in Villeurbanne, France, focused on developing nanomedicines for cancer treatment, specifically utilizing radiotherapy. The company's lead product, AGuIX, is a theranostic nanoparticle designed to enhance the localization of solid tumors and improve the effectiveness of radiation therapy. AGuIX allows for the determination of optimal irradiation timing and is capable of treating radioresistant cancers while minimizing radiation exposure to healthy tissues, thereby reducing secondary effects. Founded in 2015, NH TherAguix is dedicated to advancing innovative solutions in cancer care through its pioneering research and development efforts.

Igyxos S.A. is a French company based in Nouzilly that focuses on developing pharmaceuticals and medical technologies aimed at enhancing human fertility. Established in 2017, Igyxos engages in all stages of drug development, beginning with the discovery of promising targets and progressing to the identification of lead compounds, including small molecules and monoclonal antibodies. The company specializes in developing solutions that improve the efficacy of gonadotropins and hormones critical for reproduction. Igyxos also facilitates the transition of potential drug candidates through pre-clinical and clinical phases, aiming to address the increasing global demand for effective infertility treatments for both men and women.

Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Advicenne is a late-stage biopharmaceutical company founded in 2007 and headquartered in Nîmes, France. The company focuses on developing and commercializing innovative treatments for unmet medical needs in nephrology, particularly targeting orphan renal diseases and niche neurology indications. Its lead drug candidate, ADV7103, is undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the lives of patients from early childhood through adulthood.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.